GE HealthCare Forecasts 2025 Adjusted EPS Of $4.61-$4.75 Versus Consensus Of $4.66

Benzinga
02-13

2025 guidance

Today, the Company introduces 2025 full-year guidance, which includes the estimated impact from recently implemented U.S. tariffs on products from China.

2025 guidance is as follows:

  • Organic revenue growth of 2% to 3% year-over-year, which reflects continued demand for our products and services as well as a measured view of market conditions in China
  • Adjusted EBIT margin of 16.7% to 16.8%, reflecting an expansion of approximately 40 to 50 basis points versus 2024 Adjusted EBIT margin of 16.3%
  • Adjusted effective tax rate (ETR) in the range of 22% to 23%
  • Adjusted EPS in the range of $4.61 to $4.75, representing 3% to 6% growth versus Adjusted EPS* of $4.49 for 2024
  • Free cash flow of at least $1.75 billion

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10